...
首页> 外文期刊>Journal of oncology >Bioinformatics Analysis of Potential Therapeutic Targets and Prognostic Biomarkers amid CXC Chemokines in Ovarian Carcinoma Microenvironment
【24h】

Bioinformatics Analysis of Potential Therapeutic Targets and Prognostic Biomarkers amid CXC Chemokines in Ovarian Carcinoma Microenvironment

机译:卵巢癌微环境中CXC趋化因子潜在治疗靶标和预后生物标志物的生物信息学分析

获取原文
           

摘要

Background . Ovarian cancer (OC) is one of the leading lethal gynecologic cancers of women around the world. More than 70% of patients are diagnosed with stage III or IV with poor outcome. This is partly because of lacking early effective screening techniques and potential biomarkers of OC. CXC chemokines in tumor microenvironment (TME) and their interaction with relative receptors can excite the downstream signaling pathways to influence tumor progression. However, the role of CXC chemokines in OC has not been identified. Methods . ONCOMINE, GEPIA, Kaplan–Meier plotter, cBioPortal, TIMER, Metascape, and LinkedOmics were applied in our study. Results . The transcriptional levels of CXCL1/8/9/10/11/12/13/14/16/17 were significantly elevated while CXCL3 was obviously reduced in OC vs normal ovarian tissue. CXCL8/9/11/13 were correlated with clinic pathological stage. Patients with low expression of CXCL8/9/11/13 were associated with better prognosis. We also found that CXCL3 and CXC12 could be used as potential prognostic markers of OC through Kaplan–Meier plotter. Patients with high expression of CXCL3/12 had a significantly better prognosis. Their functions focus on locomotion, signaling, response to stimulus, undergoing the process of multiorganism, immune system, biological regulation, etc. The differentiated CXC chemokines mainly participate in cytokine-cytokine receptor interaction, chemokine signaling pathway, IL-17 signaling pathway, and toll-like receptor signaling pathway. Our results showed that CXC chemokines were highly correlated with infiltration of immune cells. The kinase targets of differentially expressed CXC chemokines are mainly in ATM, LYN, LCK, PLK1, FYN, CDK2, and ATR. Conclusions . Our results may provide a new insight for selecting precision biomarkers of targeted therapy of OC.
机译:背景 。卵巢癌(OC)是世界各地妇女的主要致死妇科癌症之一。超过70%的患者被诊断为III期或IV阶段,结果差。这部分是因为缺乏早期有效的筛查技术和of oc的潜在生物标志物。 CXC趋化因子在肿瘤微环境(TME)中及其与相对受体的相互作用可以激发下游信号通路以影响肿瘤进展。然而,尚未确定CXC趋化因子在OC中的作用。方法 。在我们的研究中应用了oncommine,Gepia,Kaplan-Meier绘图仪,Cbioportal,Timer,ForeScape和LinkedoMics。结果 。 CXCL1 / 8/9 / 10/11 / 12/13 / 14/16 / 17的转录水平显着升高,而CXCL3明显降低了OC VS正常卵巢组织。 CXCL8 / 9/11 / 13与临床病理阶段相关。 CXCL8 / 9/11/13表达低的患者与更好的预后相关。我们还发现CXCL3和CXC12可以用作OC通过Kaplan-Meier绘图仪的潜在预后标志物。 CXCL3 / 12高表达患者具有明显更好的预后。它们的功能专注于运动,发信号,对刺激的响应,正在进行多功能,免疫系统,生物调节等过程。分化的CXC趋化因子主要参与细胞因子 - 细胞因子受体相互作用,趋化因子信号通路,IL-17信号通路,以及TOLS的受体信号传导途径。我们的研究结果表明,CXC趋化因子与免疫细胞浸润高度相关。差异表达CXC趋化因子的激酶靶标主要在ATM,LYN,LCK,PLK1,FYN,CDK2和ATR中。结论。我们的结果可能为选择OC的靶向治疗的精密生物标志物提供新的洞察。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号